Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study

References

• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165–76
   PubMed Web of Science ®Google Scholar
• Rubens RD. Bone metastases—the clinical problem. Eur J Cancer 1998;34:210–3
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s–9s
   PubMed Web of Science ®Google Scholar
• Katzer A, Meenen NM, Grabbe F, et al. Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002;122:251–8
   PubMedGoogle Scholar
• Loblaw DA, Wu JS, Kirkbride P, et al. Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial. Support Care Cancer 2007;15:451–5
   PubMedGoogle Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579–84
   PubMed Web of Science ®Google Scholar
• Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390–6
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341–7
   PubMedGoogle Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317–22
   PubMed Web of Science ®Google Scholar
• Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care 2010;19:755–60
   PubMed Web of Science ®Google Scholar
• Hechmati G, Hoefeler H, Bahl A, et al. Skeletal-related events in patients with bone metastases lead to considerable health resource utilisation in Europe: analysis of a multinational observational study. Value Health 2011;14:A168
   Google Scholar
• National Institute of Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment. Full Guideline. 2009. London: NICE. http://guidance.nice.org.uk/CG81/Guidance/pdf/English. Accessed July 5, 2012
   Google Scholar
• National Institute of Clinical Excellence (NICE). The diagnosis and treatment of lung cancer (update). Full Guideline. 2011. London: NICE. http://guidance.nice.org.uk/CG121/Guidance/pdf/English. Accessed July 5, 2012
   Google Scholar
• National Institute of Clinical Excellence (NICE). Metastatic spincal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. Full Guideline. 2008. London: NICE. http://guidance.nice.org.uk/CG75/Guidance/pdf/English. Accessed July 5, 2012
   Google Scholar
• Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 2006;24:4–12
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613–21
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082–92
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314–21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150–7
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879–82
   PubMed Web of Science ®Google Scholar